Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05943067 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT

Study acronym: CD45RADLIHaplo
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv3
  2. Eligibility criteria expanded, about 5 words
    • Study description expanded, about 5 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
Trial Details
NCT Number NCT05943067
Lead Sponsor University Hospital Tuebingen
Conditions
(from sponsor)		 Hematologic Malignancy
Related terms Hematologic Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov